Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro’s utility in cardiac implantable electronic device (CIED) procedures —

SILVER SPRING, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the initiation of an EluPro™ clinical study designed to collect patient outcome data in real-world clinical practice. EluPro, the first and only FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators, was this year. The first patient was enrolled at UC San Diego Health.

“Every innovation we pursue is driven by a commitment to improving patient care,” said Kimberly Mulligan, PhD, Vice President and General Manager of Cardiovascular at Elutia. “With EluPro, we combined trusted antibiotics with a soft, regenerative biomatrix to protect the implant, facilitate implantation, and support healing. This study will allow us to collect data on these differentiating characteristics in real-world practice.”

The multi-center clinical study is a prospective, post-market study designed to evaluate the use of EluPro in standard clinical practice and its performance across a diverse population of patients undergoing CIED implantation. Data on clinical and patient-reported outcomes will be collected, which will include assessments of key complications of interest following CIED implantation - such as infection, hematoma, lead dislodgement, device migration or erosion, and implant site complications. The study plans to enroll 100 patients, who will be followed for 12 months after device implantation.

Each year, more than 600,000 CIEDs are implanted in the U.S., with overall complication rates up to 5-7%, including infections linked to higher morbidity and mortality. EluPro is cleared for use across all major CIED brands including pacemakers and implantable defibrillators, as well as for a wide range of neurostimulation devices. Unlike synthetic alternatives, EluPro addresses this critical need by combining the antibiotics rifampin and minocycline with a soft, regenerative biomatrix that promotes healing and helps reduce other complications, such as migration and erosion. The CIED protection market is valued at $600 million in the U.S.

To learn more, visit .

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning the EluPro Registry Study, including the timing and anticipated data, and the value of the CIED protection market. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to successfully commercialize, market and sell our newly approved EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the November 2023 sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; and our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia’s other filings with the SEC, accessible on the SEC’s website at and the Investor Relations page of Elutia’s website at Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investors:

Matt Steinberg

FINN Partners

This press release was published by a CLEAR® Verified individual.